Pharmaceutical

Oncolys BioPharma Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer

Oncolys BioPharma Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer

articleOncolys Biopharma, Inc.June 8, 20265/news/oncolys-biopharma-announces-full-marketing-approval-in-japan-for-telomelysin-for-the-treatment-of-esophageal-cancer-1
Oncolys BioPharma Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer

About this update from Oncolys Biopharma, Inc.

Oncolys Biopharma, Inc. (4588) Press ReleaseView Attachment

View stock analysis, news, and events for Oncolys Biopharma, Inc.